Skip to content
Study details
Enrolling now

MOCHA Trial: Montelukast After ACL Reconstruction

Austin V Stone
NCT IDNCT04572256ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

30

Study length

about 6.4 years

Ages

25–50

Locations

1 site in KY

What this study is about

Researchers are testing whether taking montelukast, a medication, after an ACL reconstruction can reduce inflammation and slow down cartilage breakdown. The trial will involve adults who have had ACL surgery with meniscal tears or post-traumatic osteoarthritis. Participants will be randomly assigned to take either montelukast or a placebo for 6 months.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Montelukast
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

montelukast (Leukotriene receptor antagonist; reduces inflammation in airways)

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Knee injury and Osteoarthritis Outcome Score (KOOS), Shape of the medial femoral condyle on MRI, T1rho relaxation time on MRI